Amedrix GmbH, an Esslingen, Germany-based developer and producer of medical devices for the regeneration of soft tissue defects based on native collagen solutions, raised €700,000 in start up financing.
Investors in the newly founded company include High-Tech Gruenderfonds (HTGF) and Life Science Fonds Esslingen.
The funds will enable the company to undertake the necessary steps to get approval for the first products, which consist of collagen solutions, spumes, membranes, sponges and fleeces and to build up its own production.
The Amedrix’s device range vary in form, size and thickness to cater for a broad range of defect treatment.
The first products, which will be distributed through partners already established in the market, will be launched in 2010.